- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Facing class action lawsuit over insulin pricing, Novo Nordisk inks $100M settlement with disgruntled investors | ||
| Fr | Gilead, Merck and others slapped with 'pay-for-delay' lawsuits over lucrative HIV and cholesterol meds | ||
| Fr | FDA's ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindo | ||
| Fr | Responding to global vaccine demand, Cytiva pledges $52.5 million to build South Korean factory | ||
| Fr | Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight | ||
| Fr | Regeneron and Roche's COVID drug wins WHO backing, but agency calls for lower prices and better access | ||
| Fr | AstraZeneca, Merck target broad use of Lynparza in prostate cancer as PARP rivals Pfizer, J&J, Clovis loom | ||
| Fr | Fierce Pharma Asia-Enhertu's big win; Biogen-Samsung's Lucentis biosimilar; Clover's COVID vaccine data | ||
| Do | CDMO Lonza strikes deal with Allarity Therapeutics to manufacture cancer drug candidate dovitinib | ||
| Do | Takeda breached its contract with AbbVie by failing to supply prostate cancer drug Lupron, court rules | ||
| Do | Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy | ||
| Do | Vaccine players in Argentina, Brazil selected as regional producers for COVID-19 shots | ||
| Do | Amid heated debate, FDA hands limited nod to Pfizer for COVID-19 vaccine boosters | ||
| Do | On a JAK roll, Incyte wins FDA green light to expand Jakafi in chronic graft-versus-host disease | ||
| Do | Pfizer CEO Bourla asks employees to join the scrum for D.C. drug-pricing fight | ||
| Do | Takeda breaks ground on $14M green building at Singapore manufacturing plant | ||
| Do | Do not enter: Biogen reps banned from D.C.-area neurology clinics over controversial Alzheimer's drug Aduhelm | ||
| Do | Small but formidable activist investor Bluebell takes stake in GlaxoSmithKline, asks CEO Walmsley to reapply for job: FT | ||
| Mi | Reckitt's Mucinex ushers in cold and flu season with tribute to Latinos making a difference | ||
| Mi | Lonza's march of manufacturing expansion continues with more backyard plans | ||
| Mi | Play-by-play: How Sanofi jacked up its offer twice to seal the $1.9B deal for Kadmon | ||
| Mi | With $68.2M investment from India's Serum, Oxford Biomedica set to add capacity and 120 jobs at its 'Oxbox' site | ||
| Mi | Novartis reshuffling doesn't portend a pullback from gene therapy, company says | ||
| Mi | Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analyst | ||
| Mi | Pfizer, Moderna, AstraZeneca and other COVID vaccine companies face urgent calls to ramp up access around the world |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
